Reversing tumour resistance to kinase inhibitors

Reversing tumour resistance to kinase inhibitors

Biopharma Reversing tumour resistance to kinase inhibitors   Drug resistance is behind most relapses in cancer patients. This is partly why anti-cancer drugs targeting oncogenic kinase signalling have failed to live up to expectations. Kinase inhibitors are only...
Restorative treatments for osteoarthritis

Restorative treatments for osteoarthritis

Biopharma Restorative treatments for osteoarthritis   There’s no cure for osteoarthritis. Current treatment for this debilitating joint disease involves managing symptoms and replacing joints. Professor Francesco Dell’Accio and his team have invented three novel and...
Reversing tumour resistance to kinase inhibitors

Single molecule biochips

Technology & Engineering Single molecule biochips   Acute Traumatic Coagulopathy, a term first coined by Queen Mary’s Karim Brohi in 2003, occurs when traumatic bleeding leads to abnormal blood clotting. The result is more severe bleeding, organ failure, and...
Controlled release of pain management drugs

Controlled release of pain management drugs

Technology & Engineering Controlled release of pain management drugs   Conventional drugs used to manage pain and inflammation suffer from a burst release issue – you get a large dose all in one go, which quickly fades. This means that patients with severe...
Using n-3 DPA-derived Resolvins for Cardiovascular Diseases

Using n-3 DPA-derived Resolvins for Cardiovascular Diseases

Biopharma Using n-3 DPA-derived Resolvins for Cardiovascular Diseases   A novel therapeutic strategy, using n-3 DPA-derived resolvins to treat or prevent cardiovascular disease. Circadian rhythms play a key role in regulating various physiological functions, including...